Active — Not RecruitingNot Applicable

Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension

Canada, Germany40 participantsStarted 2011-06

Plain-language summary

To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.

Who can participate

Age range21 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Actively participating in the Neo Non-Randomized Hypertension Study. * Have signed a revised approved informed consent form for continued participation in this study. Exclusion Criteria: * Treating physician decision that the subject should not continue with therapy.

What they're measuring

To access long-term adverse events in participants implanted with the BAROSTIM NEO System.

Timeframe: For the duration of the study, up to 10 years.

Trial details

NCT IDNCT01471834

SponsorCVRx, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-05

View on ClinicalTrials.gov More High Blood Pressure trials